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DERIVATIVES OF ASPIRIN 
CROSS-REFERENCE TO RELATED 
APPLICATION 
Hussain et al copending application, Ser. No. 043,814, 
?led concurrently herewith, and.he'reby expressly in 
corporated by reference. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to 2-acetoxybenzoic 
acid and more particularly, the present invention relates 
to therapeutically useful derivatives of Z-acetoxyben 
zoic acid, which are substituted l-O-(2'-acetoxy)benz 
oyl-a-D-2-deoxyglucopyranose derivatives. 
The novel compounds of this invention exhibit anal 
gesic, antipyretic, and antirheumatic therapeutic activ 
ity. 
The compound 2-acetoxybenzoic acid is commonly 
known as “aspirin” and/or “acetylsalicylic acid”, and is 
one of the most widely used compounds in the treat 
ment of simple pain and in?ammation. Z-Acetoxyben 
zoic acid is widely employed as an analgesic, an antipy 
retic, and anti-in?ammatory and an antirheumatic 
agent, and it is particularly useful in the relief of fever, 
headache, myalgia, arthralgia and other pains associ 
ated with integumental structures. Z-Acetoxybenzoic 
acid is generally administered for these conditions in the 
form of powder, particle, capsule, solution, tablet or 
other pharmaceutically acceptable dosage form because 
it is advantageous from the standpoint that chronic use 
of the compound will not lead to a tolerance or addic 
tion thereof. Moreover, its toxicity is much lower than 
most compounds possessing similar pharmacologic ac 
tivity. However, Z-acetoxybenzoic acid, as used for 
these purposes, is well-known by the practicing skilled 
artisan of the medical arts to exhibit certain unwanted 
and deliterious side effects. Speci?cally, it induces oc 
cult hemorrhaging in the gastrointestinal tract, which 
results from contact of the insoluble solid particulate of 
the compound with the gastrointestinal mucosa. As a 
result of this insolubilization, the very acidic particles of 
2-acetoxybenzoic acid will adhere to the gastrointesti 
nal mucosa in the form of crystals and such crystals, 
taken together with the acidic environment of the gas 
trointestinal lining, will produce microetching thereof, 
‘ which in turn, leads to gastrointestinal bleeding. 
2. Description of the Prior Art 
To date, it is known that gastric bleeding can be 
diminished if (1) an aqueous solution of 2-acetoxyben 
zoic acid is administered, or (2) a buffered aqueous 
solution of 2-acetoxybenzoic acid is administered. How 
ever, such solutions leave much to be desired in that 
they are commercially and consumerwise unacceptable, 
i.e., water and/ or buffered solutions are unacceptable as 
a suitable pharmaceutical dosage form. 
' One product on the market, commercially known as 
“Alka-Seltzer ®” is basically an alkaline effervescent 
Z-acetoxybenzoic acid formulation, which does exhibit 
satisfactory water solubility and dissolution, insofar as 
2-acetoxybenzoic acid is concerned. However, at least 
three disadvantages are associated with this product. 
Firstly, the product is contained in a tablet form and 
must initially be dissolved in water prior to consump 
tion. Secondly, because the product contains a high 
amount of sodium ion, it is unacceptable for administra 
tion to hypertensive patients (those who suffer from 
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high blood pressure), because it has now been medically 
established that the sodium ion contributes to hyperten 
sion. Thirdly, the alkaline nature of the product per se 
alters the pH of the blood and urine to the alkaline side. 
Chronic use of this product could thus initiate alkalosis. 
It has also been proposed to avoid the adverse effects 
of 2-acetoxybenzoic acid by the use of various esteri?ed 
derivatives thereof, wherein transient blocking of the 
acidic carboxylic group of aspirin occurs. For instance, 
French Patent No. M1453 describes various antipyretic 
and analgesic compounds formed by esterifying 2 
acetoxybenzoic acid with various sugars. Whether such 
derivates are viable substitutes for 2-acetoxybenzoic 
acid depends not only upon whether these derivatives 
have therapeutic value per se, but to a larger extent 
upon whether these derivatives have the potential to 
revert to 2-acetoxybenzoic acid by hydrolysis in vivo. 
In this respect, it is notable that certain derivatives of 
Z-acetoxybenzoic acid tend to hydrolyze so as to form 
the corresponding ester of salicylic acid and not aspirin. 
The following reaction scheme serves to illustrate the 
manner in which derivatives of Z-acetoxybenzoic acid 
may hydrolyze: 
ll ll 
c-o-a c-o-u 
Z-Acetoxybenzoic Acid Ester Z-Acetoxybenzoic Acid 
(11) 
Salicylic Acid Ester 
It is apparent that only those esteri?ed derivatives of 
Z-acetoxybenzoic acid which hydrolyze according to 
reaction scheme (I), so as to produce aspirin, are viable 
substitutes for aspirin. Also, such a substitute must hy 
drolyze at a rate sufficient to release aspirin in therapeu 
tically effective quantities. 
It has recently been discovered that the aspirin deriv 
ative, l-O-(2’-acetoxy)benzoyl-a-D-glucopyranose, 
tends to hydrolyze so as to form the corresponding 
sugar derivative of salicylic acid, as per reaction scheme 
(II) depicted above. Furthermore, to the extent that 
hydrolysis to aspirin takes place, such hydrolysis takes 
place only at a very slow rate. Cf. the aforenoted Hus 
sain et al application, Ser. No. 043,814. 
In summary, the various prior art sugar derivatives of 
2-acetoxybenzoic acid present a non-irritating neutral 
molecule to the gastrointestinal lining when adminis 
tered for therapeutic purposes. However, the group 
which blocks the carboxylic acid function of Z-acetox 
ybenzoic acid tends to be bound thereto very tightly. 
Such prior art derivatives, therefore, do not release 
aspirin in vivo in therapeutically suf?cient quantities. 
Thus, a need exists for a 2-acetoxybenzoic acid deriva 
tive, wherein transient blocking of the carboxylic func 
tion occurs, yet wherein the blocking group is not so 
tenaciously bound thereto. 
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SUMMARY OF THE INVENTION 
Accordingly, it is onelobject of the present invention 
to provide a derivative of Z-acetoxybenzoic acid which 
does not tend to cause local irritation of the gastrointes 
tinal tract, yet which is capable of hydrolyzing at a rate 
sufficient to release 2-acetoxybenzoic acid in vivo in 
therapeutically sufficient quantities. - 
It is another object of the present invention to pro 
vide a derivative of 2-acetoxybenzoic‘acid which will 
permit a therapeutically effective compound to be ab 
sorbed through the gastrointestinal lining, in a manner 
such that insoluble, acidic particles of Z-acetoxybenzoic 
acid are not contacted therewith, thus eliminating gas 
trointestinal bleeding. I 
Finally, it is yet another object of ‘the present inven 
tion, to provide a derivative of 2-acetoxybenzoic acid, 
which can be formulated in a suitable oral pharmaceuti 
cally acceptable dosage form forpadministration as an 
analgesic, an antipyretic, an anti-in?ammatory and an 
antirheumatic agent to warm-blooded animals. 
These and other objects of the instant invention will 
become more readily apparent from a reading of the 
accompanying disclosure and appended claims thereto. 
The foregoing objects are attained with the use of 
novel acylal derivatives of 2-acetoxybenzoic acid, the 
structure of which may be represented by the following 
formula I 
wherein R represents amino, lower monoalkylamino, 
lower dialkylamino, 7 lower alkyl, lower cycloalkyl, 
lower hydroxy-substituted alkyl, lower alkoxy or piper 
idino. 
DETAILED DESCRIPTION OF THE 
INVENTION 
If the substituent R within the compounds of formula 
I includes lower alkyl groups, these alkyl group contain 
e.g., 1-4 carbon atoms. If the lower alkyl is unsubsti 
tuted, methyl is preferred; in the case of hydroxy‘substi 
tuted alkyl, 2-hydroxy-alkyl is preferred. Lower cyclo 
alkyl groups R may comprise e.g., 3-5 carbon atoms. 
The compounds of formula I can be synthesized ac 
cording to the following scheme: 
R 
OH on 
CH3OH + HO HO $?-cm-o HO 
0 o 
cnzon cnzou 
(I) 
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-continued 
R 
} CHZCI UB2 
1 + KOH B20 ( ) HEAT 9 CHFO 
B2 = —CH2¢ O 
CHZOBZ 
(II) 
R 
0132 
GLACIAL ACETIC ACID B20 
(u) 2N H2504 HEAT 9H0 
o 
CHZOBZ 
(HA) 
0 
ll 
c-c1 
(HA) + PYRIDINE ; 
o-c-cu; 
ll 
0 
ll 
c-—o—-nA 
O-—?—Cl-I3 
(111) 0 
R 
H OH 
C_O H0 
H2 - Pd/C 
(In) + O 
O-?-CH; CHZOH 
' 0 PRODUCT 
The above‘ method is basically a modi?cation of the 
method reported by Glaudemans and Fletcher in Meth 
ods 0f Carbonhydrate Chemistry, Volume VI, R. I... 
Whistler and J. N. Bemiller, Eds., Academic Press, 
New York, NY. (1972), pp. 373-376. 
Numerous modi?cations in the depicted reaction 
scheme will be apparent to those skilled in the art. For 
example, protecting groups other than benzyl can be 
employed, so long as they can be readily removed after 
coupling of the substituted a-D-Z-deoxyglucopyranose 
and the 2-acetoxybenzoic acid portions of the molecule. 
Thus, p-methoxybenzyl or tert-butyl radicals could be 
introduced into the glucopyranose derivative instead of 
the benzyl protecting groups. After coupling, benzyl 
and p-methoxybenzyl protecting groups can be conve 
niently removed by catalytic hydrogenolysis. Suitable 
catalysts may include rhodium, platinum, ruthenium, 
Raney nickel, and palladium (optionally on a support), a 
particularly preferred catalyst being palladium-on-car 
bon. When protecting groups which are normally not 
sensitive to catalytic hydrogenolysis, e.g., tert-butyl 
radicals, are employed, removal may be effected by use 
of an acid such as trifluoroacetic acid. If R is hydroxyal 
kyl group, the latter, of course, will react towards any 
protective group in the same manner as the hydroxy~ 
methyl group in 5-position of the glucopyranose nu 
cleus. 
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possible. For example, the acid chloride starting mate 
rial could be reacted with the protectedglucopyranose 
in the presence of suitable bases other than pyridine, 
e.g., other tertiary aliphatic oraromatic amines such as 
N~methylmorpholine, triethylamine, and picoline, con; 
veniently in -a non-protic solvent.-,Alternatively,. the 
protected glucopyranose could be. reacted with 2 
acetoxybenzoic acid (rather than with?the acid chlo 
ride), in which case the reaction would be conductedin 
the presence of a suitable dehydrating agent, for exam 
ple, an aromatic or aliphatic carbodiimide. ' 
The rate of generation of aspirin via hydrolysis of its 
derivatives of the present invention can be determined 
spectrophotometrically. Determination of rate of gener 
ation of aspirin from its pro-drugs according to the 
present invention were made using solutions ranging 
from pH 1.2 to pH 9. 
The generation of aspirin from the derivatives was 
found to be largely independent of the pH of the solu 
tions. The half-life for the hydrolysis at pH 3 and pH 8 
at 37° C. was found to be in the range of several min 
utes, e.g., between 5 and 10 minutes. 
20 
Thus, the transient blocking of the acidic carboxylic I 
group of aspirin by formation of an acylal-linked deriva 
tive results in a compound which regenerates aspirin at 
an acceptablerate. Such a compound reduces the gas 
trointestinal liability of aspirin by presenting a neutral 
molecule to the gastric membrane. , I 
The compounds of this invention are conveniently 
administered in oral dosage form, such as by tablet or 
capsule, by combining the same in a therapeutic amount 
(e. g., dosage regimen for aspirin on an equivalent 
weight basis) with any oral pharmaceutically accept 
able inert carrier, such as lactose, starch (pharmaceuti 
cal grade), dicalcium phosphate, calcium sulfate, kaolin, 
mannitol, and powdered sugar. In addition, when re 
quired, suitable binders, - lubricants, disintegrating 
agents, and coloring agents can also be added. Typical 
binders include starch, gelatin, sugars, such as sucrose, 
molasses, and lactrose, natural and synthetic gums such 
as acacia, sodium alginate, extract of Irish moss, carbox 
ymethylcellulose, methylcellulose, and polyvinylpyr 
rolidone, polyethyleneglycol, ethylcellulose and waxes. 
Typical lubricants for use in these dosage forms can 
include, without limitation, sodium benzoate, sodium 
acetate, sodium chloride, leucine and polyethyleneg 
lycol. Suitable disintegrators can include, without limi 
tation, starch, methylcellulose, agar, bentonite, cellu 
lose and wood products, alginic acid, guar gum, citrus 
pulp, carbonmethylcellulose and sodium lauryl sulfate. 
If desired, a conveniently pharmaceutically acceptable 
dye can be incorporated into the dosage unit form, i.e., 
any of the standard FD&C dyes. 
Any skilled artisan can prepare these oral dosage 
forms by simply referring to the oral dosage form pre 
paratory procedure outlined in “REMINGTON’S 
PHARMACEUTICAL SCIENCES,” Fourteenth 
Edition (1970), pp. 1659-1698, inclusive. 
The dose administered, whether a single dose or a 
daily dose will, of course, vary with the needs of the 
individual being treated. However, the dosage adminis 
tered is not subject to de?nite bounds, but it will usually 
be an effective therapeutic amount, or the equivalent on 
a molar basis of the pharmacologically-active form 
produced upon the metabolic release of the active drug 
(Z-acetoxybcnzoic acid) to achieve its desired pharma 
cological or physiological effect. 
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.‘Although the present invention has been adequately 
described in the foregoing speci?cation, it is, apparent 
that various changes and/or modifications can belmade 
thereto by the skilled artisan without departing from the 
spirit and scope thereof. Such changes and/or modi?ca 
tions are properly, equitably and intended to be within 
the full range of equivalence of the following claims: 
What. is claimed is: ' 
1. An . l-O-(2’acetoxy)benzyl-d-D-2-deoxy 
glucopyranose derivative having the formula 
R 
if 0H 
C_O HO 
0 
CHZOI-I 
wherein R represents amino, lower monoalkylamino, 
lower dialkylamino, piperidino, lower alkyl, lower cy 
cloalkyl, lower alkoxy or hydroxy-substituted lower 
alkyl. 
2. A method for inducing an analgesic, antipyretic, 
antirheumatic or anti-in?ammatory response in a warm 
blooded animal which comprises orally administering 
thereto an effective amount of l-O-(2’-acetoxy)benzoyl 
a-D-Z-deoxyglucopyranose derivative as de?ned in 
claim 1; 
3. A pharmaceutical composition of matter adapted 
for oral administration comprising an effective analge 
sic, antipyretic, antirheumatic or anti-in?ammatory 
amount of an 1-O-(2'-acetoxy)benzoyl-a-D-2-deoxy 
glucopyranose derivative as de?ned in claim 1 and a 
pharmaceutically acceptable inert carrier. 
4. The compound as de?ned by claim 1, wherein R is 
amino. 
5. The compound as de?ned in claim 1, wherein R is 
lower alkyl. 
6. The compound as de?ned in claim 1, wherein R is 
lower monoalkylamino. 
7. The compound as de?ned in claim 1, wherein R is 
lower dialkylamino. 
8. The compound as de?ned in claim 1, wherein R is 
piperidino. 
9. The compound as de?ned in claim 1, wherein R is 
lower cycloalkyl. 
10. The compound as de?ned in claim 1, wherein R is 
lower alkoxy. 
11. The compound as de?ned in claim 1, wherein R is 
hydroxy-lower alkyl. 
12. The compound as de?ned by claim 5, wherein R 
is methyl. 
13. The compound as de?ned by claim 11, wherein R 
is 2-hydroxyalky1. 
14. A compound having the structural formula: 
4,241,055 
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wherein R represents amino, lower monoalkylamino, 
lower dialkylamino, piperidino, lower alkyl, lower cy 
cloalkyl, lower alkoxy or hydroxyvsubstituted lower 
alkyl, and R‘ is selected from the group consisting of 
benzyl, p-methoxybenzyl and tert-butyl. 
15. The method as de?ned by claim 2, for inducing an 
analgesic response. 
16. The method as de?ned by claim 2, for inducing an 
antipyretic response. 
17. The method as de?ned by chim 2, for inducing an 
antirheumatic response. 
0 
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18. The method as de?ned by claim 2, for inducing an 
anti-inflammatory response. 
19. The composition as de?ned by claim 3, compris 
ing an analgesic amount of said derivative. 
20. The composition as de?ned by claim 3, compris 
ing an antipyretic amount of said derivative. 
21. The composition as de?ned by claim 3, compris 
ing an antirheumatic amount of said derivative. 
22. The composition as de?ned by claim 3, compris 
ing an anti-inflammatory amount of said derivative. 
* it i i ll! 
